COMP <GO>
PCVX vs MRK // NET PROFIT MARGIN
Vaxcyte Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: PCVX 3
— MRK 11
▲ NET PROFIT MARGIN LEADER: MRK
LAST: $62.03 (-0.93%) • MKT CAP: $9.85B
net-margins
0.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCVX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCVX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.60% | 20.70% | -48.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.79% | 3.42% | -10.21 | MRK | /fcf-yield <GO> |
| Operating Margin | -33.50% | 34.30% | -67.80 | MRK | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 0.00% | 28.10% | -28.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 19.80% | 1.30% | +18.50 | PCVX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.11 | 5.19 | +12.92 | PCVX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 56.9 | -8.05 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.92 | +0.15 | PCVX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 18.4x | +4.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.85B | $361.02B | -$351.17B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCVX REV | MRK REV | PCVX GROSS % | MRK GROSS % | PCVX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.01B | — | 74.8% | -$669.3M | $12.36B |
| FY 2024 | $0 | $64.17B | — | 76.3% | -$475.1M | $18.10B |
| FY 2023 | $0 | $60.12B | — | 44.0% | -$296.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCVX // BETA 1.07
MRK // BETA 0.92